Retraction notices

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

Type
Correction
Notice date
11/1/2018 0:00
Journal
Cancer Discovery
Publisher
American Association for Cancer Research
Notice DOI
10.1158/2159-8290.cd-18-1114
Original paper DOI
10.1158/2159-8290.cd-16-0512

Reasons

Matching venue names

Name match only, not an authoritative journal identifier.